Plasminogen activator inhibitor-1 4G/5G promoter polymorphism and coagulation factor VII Arg353→Gln polymorphism in Korean patients with coronary artery disease

Journal of Korean Medical Science

Volumn 15, Issue 2, 2000, Pages 146-152

  Song, Junghan ^a   Yoon, Yeo Min ^a   Jung, Hyun Jin ^a   Hong, Seung Ho ^a   Park, Hyosoon ^b   Kim, Jin Q ^a  

^a Seoul National University   (South Korea)

^b Sungkyunkwan University   (South Korea)

Author keywords

Coronary Disease; Factor VII; Plasminogen Activator Inhibitor 1; Polymorphism (Genetics)

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B; BLOOD CLOTTING FACTOR 7; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL;

AGED; ALLELE; ARTICLE; BLOOD; CORONARY ARTERY DISEASE; FEMALE; GENETICS; GENOTYPE; HUMAN; KOREA; MALE; MIDDLE AGED; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; ALLELES; APOLIPOPROTEINS A; APOLIPOPROTEINS B; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; FACTOR VII; FEMALE; GENOTYPE; HUMANS; KOREA; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS (GENETICS); TRIGLYCERIDES;

EID: 0034167004     PISSN: 10118934     EISSN: None     Source Type: Journal    
DOI: 10.3346/jkms.2000.15.2.146     Document Type: Article

References (37)

1. Wiman B. Plasminogen activator inhibitor 1 (PAI-1) in plasma: its role in thrombotic disease. Thromb Haemost 1995; 74: 71-6.
2. Hamsten A, de Faire U, Walldius G, Dahlén G, Szamosi A, Landou C, Blomback M, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 2: 3-9.
3. Ny T, Sawdey M, Lawrence D, Millan J, Loskutoff DJ. Cloning and sequencing of a cDNA coding for the human B-migrating endothelial cell type plasminogen activator inhibitor. Proc Natl Acad Sci USA 1986; 83: 6776-80.
4. Klinger KW, Winqvist R, Riccio A, Andreasen PA, Sartorio R, Nielsen LS, Stuart N, Stanislovitis P, Watkins P, Douglas R, Grzeschik KH, Alitalo K, Blasi F, Dano K. Plasminogen activator inhibitor type 1 gene is located at region q21.3-q22 of chromosome 7 and genetically linked with cystic fibrosis. Proc Natl Acad Sci USA 1987; 84: 8548-52.
5. Dawson S, Hamsten A, Wiman B, Henney A, Humphries S. Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb 1991; 11: 183-90.
6. Humphries SE, Lane A, Dawson S, Green FR. The study of gene-environment interactions that influence thrombosis and fibrinolysis. Genetic variation at the loci for factor VII and plasminogen activator inhibitor-1. Arch Pathol Lab Med 1992; 116: 1322-9.
7. Eriksson P, Kallin B, van't Hooft FM, Bavenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen - activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995; 92: 1851-5.
8. Mansfield MW, Stickland MH, Grant PJ. Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor-1 in Caucasian patients with non-insulin-dependent diabetes mellitus. Thromb Haemost 1995; 74: 842-7.
9. McCormack LJ, Nagi DK, Stickland MH, Mansfield MW, Mohamed-Ali V, Yudkin JS, Knowler WC, Grant PJ. Promoter (4G/5G) plasminogen activator inhibitor-1 genotype in Pima Indians: relationship to plasminogen activator inhibitor-1 levels and features of the insulin resistance syndrome. Diabetologia 1996; 39: 1512-8.
10. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR, Haines AP, Stirling Y, Imeson JD, Thompson SG. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; 2: 533-7.
11. Hoffman CJ, Miller RH, Lawson WE, Hultin MB. Elevation of factor VII activity and mass in young adults at risk of ischemic heart disease. J Am Coll Cardiol 1989; 14: 941-6.
12. Broadhurst P, Kelleher C, Hughes L, Imeson JD, Raftery EB. Fibrinogen, factor VII clotting activity and coronary artery disease severity. Atherosclerosis 1990; 85: 169-73.
13. Hagen FS, Gray CL, O'Hara P. Characterization of a cDNA coding for human factor VII. Proc Natl Acad Sci USA 1986; 83: 2412-6.
14. Green F, Kelleher C, Wilkes H, Temple A, Meade T, Humphries SA. Common genetic polymorphism associated with lower coagulation factor VII levels in healthy individuals. Arterioscler Thromb 1991; 11: 540-6.
15. Humphries SE, Lane A, Green FR, Cooper J, Miller GJ. Factor VII coagulant activity and antigen levels in healthy men are determined by interaction between factor VII genotype and plasma triglyceride concentration. Arterioscler Thromb 1994; 14: 193-8.
16. Kim JQ, Song J, Park YB, Hong SH. Molecular base of coronary heart disease in Koreans. J Korean Med Sci 1998; 13: 1-15.
17. Saha N, Liu Y, Heng CK, Hong S, Low PS, Tay JS. Association of factor VII genotype with plasma factor VII activity and antigen levels in healthy Indian adults and interaction with triglycerides. Arterioscler Thromb 1994; 14: 1923-7.
18. Kannel WB. Range of serum cholesterol values in the population developing coronary artery disease. Am J Cardiol 1995; 76: 69-77C.
19. Nagi DK, McCormack LJ, Mohamed-Ali V, Yudkin JS, Knowler WC, Grant PJ. Diabetic retinopathy, promoter (4G/ 5G) polymorphism of PAI-1 gene, and PAI-1 activity in Pima Indians with type 2 diabetes. Diabetes Care 1997; 20: 1304-9.
20. Iwai N, Shimoike H, Nakamura Y, Tamaki S, and Kinoshita M. The 4G/5G polymorphism of the plasminogen activator inhibitor gene is associated with the time course of progression to acute coronary syndromes. Atherosclerosis 1998; 136: 109-14.
21. Mansfield MW, Stickland MH, Grant PJ. Plasminogen activator inhibitor-1 (PAI-1) promoter polymorphism and coronary artery disease in non-insulin-dependent diabetes. Thromb Haemost 1995; 74: 1032-4.
22. Ye S, Green FR, Scarabin PY, Nicaud V, Bara L, Dawson SJ, Humphries SE, Evans A, Luc G, Cambou JP, Arveiler D, Henny AM, Cambien F. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Etude CasTemoins de I'nfarctus du Mycocarde. Thromb Haemost 1995; 74: 837-41.
23. Mansfield MW, Stickland MH, Carter AM, Grant PJ. Polymorphisms of the plasminogen activator inhibitor-1 gene in type 1 and type 2 diabetes, and in patients with diabetic retinopathy. Thromb Haemost 1994; 71: 731-6.
24. Catto AJ, Carter AM, Stickland M, Bamford JM. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorphism and levels in subjects with cerebrovascular disease. Thromb Haemost 1997; 77: 730-4.
25. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Miletich JP. Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men. Circulation 1997; 95: 59-62.
26. Stegnar M, Uhrin P, Peternel P, Mavri A, Salobir-Pajnic B, Stare J, Binder BR. The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: relationship to plasma PAI-1 level in venous thromboembolism. Thromb Haemost 1998; 79: 975-9.
27. Grubic N, Stegnar M, Paternel P, Kaider A, Binder BR. A novel G/A and the 4G/5G polymorphism within the promoter of the plasminogen activator inhibitor-1 gene in patients with deep vein thrombosis. Thromb Res 1996; 84: 431-43.
28. Humphries SE, Panahloo A, Montgomery HE, Green F, Yudkin J. Gene-environment interaction in the determination of levels of haemostatic variables involved in thrombosis and fibrinolysis. Thromb Haemost 1997; 78: 457-61.
29. Broch M, Gutierrez C, Aguilar C, Simon I, Richart C, Vendrell J. Genetic variation in promoter (4G/5G) of plasminogen activator inhibitor 1 gene in type 2 diabetes. Absence of relationship with microangiopathy. Diabetes Care 1998; 21: 463.
30. Panahloo A, Mohamed-Ali V, Lane A, Green F, Humphries SE, Yudkin JS. Determinants of plasminogen activator inhibitor 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene. Diabetes 1995; 44: 37-42.
31. Moor E, Silveira A, van't Hooft F, Suontaka AM, Eriksson P, Blomback M, Hamsten A. Coagulation factor VII mass and activity in young men with myocardial infarction at a young age. Role of plasma lipoproteins and factor VII genotype. Arterioscler Thromb Vasc Biol 1995; 15: 655-64.
32. Ghaddar HM, Folsom AR, Aleksic N, Hearne LB, Chambless LE, Morrissey JH, Wu KK. Correlation of factor VIIa values with factor VII gene polymorphism, fasting and postprandial triglyceride levels, and subclinical carotid atherosclerosis. Circulation 1998; 98: 2815-21.
33. Hunault M, Arbini AA, Lopaciuk S, Carew JA, Bauer KA. The Arg353Gln polymorphism reduces the level of coagulation factor VII. In vivo and in vitro studies. Arterioscler Thromb Vasc Biol 1997; 17: 2825-9.
34. Bernardi F, Marchetti G, Pinotti M, Arcieri P, Baroncini C, Papacchini M, Zepponi E, Ursicino N, Chiarotti F, Mariani G. Factor VII gene polymorphisms contribute about one third of the factor VII level variation in plasma. Arterioscler. Thromb Vasc Biol 1996; 16: 72-6.
35. Iacoviello L, Burzotta F, Di Castelnuovo A, Zito F, Marchioli R, Donati MB. The 4G/5G polymorphism of PAI-1 promoter gene and the risk of myocardial infarction: a meta-analysis. Thromb Haemost 1998; 80: 1029-30.
36. Kimura H, Gejyo F, Suzuki Y, Suzuki S, Miyazaki R, Arakawa M. Polymorphisms of angiotensin converting enzyme and plasminogen activator inhibilor-1 genes in diabetes and macroangiopathy. Kidney Int 1998; 54: 1659-69.
37. Takamiya O. Genetic polymorphism (Arg353→Gln) in coagulation factor VII gene and factor VII levels (coagulant activity, antigen and binding ability to tissue factor) in 101 healthy Japanese. Scand J Clin Lab Invest 1995; 55: 211-5.